The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.

Authors	Richard C Becker
Journal	American heart journal (Am Heart J) Vol. 150 Issue 2 Pg. 189-92 (Aug 2005) ISSN: 1097-6744 [Electronic] United States
PMID	16086916 (Publication Type: Comparative Study, Editorial)
Chemical References	Anticoagulants Enoxaparin Fibrinolytic Agents Lipoproteins lipoprotein-associated coagulation inhibitor Heparin
Topics	Anticoagulants (administration & dosage, adverse effects, pharmacology) Coronary Disease (complications, drug therapy) Drug Interactions Endothelium, Vascular (drug effects) Enoxaparin (administration & dosage, therapeutic use) Fibrinolytic Agents (administration & dosage, therapeutic use) Heparin (administration & dosage, adverse effects, pharmacology) Humans Lipoproteins (metabolism) Meta-Analysis as Topic Models, Biological Myocardial Infarction (etiology, prevention & control) Premedication Randomized Controlled Trials as Topic Thrombophilia (chemically induced) Thrombosis (prevention & control) Vasculitis (chemically induced, complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!